Article
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Nature - 6 Oct 2016
Kim Jimi, McMillan Elizabeth, Kim Hyun Seok, Venkateswaran Niranjan, Makkar Gurbani, Rodriguez-Canales Jaime, Villalobos Pamela, Neggers Jasper Edgar, Mendiratta Saurabh, Wei Shuguang, Landesman Yosef, Senapedis William, Baloglu Erkan, Chow Chi-Wan B, Frink Robin E, Gao Boning, Roth Michael, Minna John D, Daelemans Dirk, Wistuba Ignacio I, Posner Bruce A, Scaglioni Pier Paolo, White Michael A
Abstract excerpt
The common participation of oncogenic KRAS proteins in many of the most lethal human cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, has spurred persistent and intensive efforts to develop drugs that inhibit KRAS activity. However, advances have been hindered by the pervasive inter- and intra-lineage diversity in the targetable mechanisms that underlie KRAS-driven...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
